NYSE · LLY · Drug Manufacturers - General
Eli Lilly (LLY) stock analysis
- LLY gained 8.6% over the past month versus 0.0% for the S&P 500, ranking 85th of 497 S&P 500 stocks.
- Over 12 months it returned +57.6%, 41.8 points ahead of the S&P 500, and trades 1.0% below its 52-week high.
- In the last 30 days 7 analysts raised earnings estimates and 5 cut; forward EPS moved +0.3% (+5.7% over 90 days).
- It sits in the Obesity & metabolic (GLP-1) segment of the Healthcare Value Chain, where the 1-month median return is +3.8%.
- The daily chart reads Trend transition · Trend repair (since Oct 19, 2026).
One-year price with 50- and 200-day averages
Performance vs the market
Total price return against the S&P 500 (SPY) and the median of US stocks in the same sector.
Chart structure
Read by our daily-bar structure engine from swing highs, swing lows and moving averages.
Holding since Oct 19, 2026
- Close above EMA20 above EMA50
- EMA50 rose over the last ten sessions
- Intermediate and long-term directions differ
- Neither a stable trend nor a range is confirmed
46 occurrences in 10 years. The median move over the next 20 sessions was +2.8%, positive 67% of the time, against +1.9% for any day in the same period.
Analyst earnings revisions
Changes to the consensus forward-EPS estimate. Rising estimates mean analysts see more profit ahead.
29 analysts cover the stock
Where it sits in the supply chain
Healthcare Value Chain · Drugs & devices
GLP-1 drugs for weight loss and diabetes are the largest recent source of drug growth; two leaders compete on share, with supply, coverage and price as key variables.
Also on: Medtech, Diagnostics & Care · Agriculture to the Table
Figures are each company's 1-month return; the segment shows its median · Doubler daily batch · company chain maps
Risk profile
Themes
- Gene/Cell Therapy3M rank 37 / 99
Track this stock every day
Hub adds the daily brief, StockFlow factor flow, trade plans and alerts for your watchlist.